IMCR — Immunocore Holdings Share News
0.000.00%
Last trade - 00:00- $1.54bn
- $1.05bn
- $400.02m
UK's Immunocore Q2 EPS misses estimates
Immunocore Holdings PLC expected to post earnings of 1 cent a share - Earnings Preview
UK's Immunocore Q1 profit beats estimates
UK's Immunocore Q4 KIMMTRAK sales rise 24%
Moderna CMO Jacqueline Miller to step down
Immunocore Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
Brief: Immunocore Reports Second Quarter Financial Results And Provides A Business Update
Immunocore Holdings PLC expected to post a loss of 21 cents a share - Earnings Preview
Immunocore Holdings PLC reports results for the quarter ended March 31 - Earnings Summary
Brief: Immunocore Reports First Quarter Financial Results And Provides A Business Update
Immunocore Holdings PLC expected to post a loss of 39 cents a share - Earnings Preview
Immunocore Holdings PLC reports results for the quarter ended December 31 - Earnings Summary
Brief: Immunocore Qtrly Loss Per Share $0.47
Immunocore Holdings PLC expected to post a loss of 26 cents a share - Earnings Preview
Brief: Immunocore Reports Q3 Financial Results And Provides Business Update
Immunocore Holdings PLC expected to post a loss of 35 cents a share - Earnings Preview
Brief: Immunocore announces transition of Chief Financial Officer
Immunocore Holdings PLC expected to post a loss of 48 cents a share - Earnings Preview
Brief: Immunocore Announces Randomization Of First Patient In The Global, Registrational Phase 3 Clinical Trial Testing brenetafusp For The Treatment Of First-Line Advanced Or Metastatic Cutaneous Melanoma